These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7511562)

  • 1. Potential role for non-HLA-restricted cytotoxic cells in the immune surveillance of acute leukemia.
    Archimbaud E; Campos L; Vila L; Thomas X
    Immunol Lett; 1993 Dec; 39(1):13-5. PubMed ID: 7511562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
    Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
    Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible mechanism of selective killing of myeloid leukemic blast cells by lymphokine-activated killer cells.
    Oblakowski P; Bello-Fernandez C; Reittie JE; Heslop HE; Galatowicz G; Veys P; Wilkes S; Prentice HG; Hazlehurst G; Hoffbrand AV
    Blood; 1991 May; 77(9):1996-2001. PubMed ID: 1708296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
    Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
    Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of adhesion molecules on acute leukemic blast cells and sensitivity to normal LAK activity.
    Raspadori D; Lauria F; Ventura MA; Rondelli D; Tura S
    Ann Hematol; 1993 Nov; 67(5):213-6. PubMed ID: 7694662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conjugate formation by leukemic blasts from acute myeloid leukemia with cytotoxic lymphocytes.
    Palucka AK; Porwit A; Reizenstein P
    Leuk Lymphoma; 1993 Nov; 11(5-6):427-33. PubMed ID: 7907248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD18/CD54(+CD102), CD2/CD58 pathway-independent killing of lymphokine-activated killer (LAK) cells against glioblastoma cell lines T98G and U373MG.
    Komatsu F; Kajiwara M
    Oncol Res; 2000; 12(1):17-24. PubMed ID: 11061342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of leukemic blasts to lymphokine activated killer (LAK)-mediated cytotoxicity is not related to their adhesion properties.
    Palucka AK; Porwit A; Reizenstein P
    Eur J Haematol; 1991 Aug; 47(2):123-7. PubMed ID: 1716215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of CD11a/leukocyte function antigen-1 and CD54/intercellular adhesion molecule-1 on hairy cell leukemia cells is accompanied by enhanced susceptibility to T-cell but not lymphokine-activated killer-cell cytotoxicity.
    Jansen JH; van der Harst D; Wientjens GJ; Kooy-Winkelaar YM; Brand A; Willemze R; Kluin-Nelemans HC
    Blood; 1992 Jul; 80(2):478-83. PubMed ID: 1352710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells.
    Notter M; Ludwig WD; Bremer S; Thiel E
    Blood; 1993 Nov; 82(10):3113-24. PubMed ID: 7693036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors.
    Oberholtzer E; Contarini M; Veglia F; Cossarizza A; Franceschi C; Geuna M; Provinciali M; Di Stefano G; Sissom J; Brizzi MF; Pegoraro L; Matera L
    Adv Neuroimmunol; 1996; 6(3):233-47. PubMed ID: 8968423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells.
    Altomonte M; Gloghini A; Bertola G; Gasparollo A; Carbone A; Ferrone S; Maio M
    Cancer Res; 1993 Jul; 53(14):3343-8. PubMed ID: 7686816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.
    Archimbaud E; Thomas X; Campos L; Magaud JP; Fiere D; Doré JF
    Leukemia; 1991 Nov; 5(11):967-71. PubMed ID: 1961038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis.
    Savary CA; Lotzová E
    Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
    Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
    Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific recognition of human leukemic cells by allogeneic T cell lines.
    Sosman JA; Oettel KR; Hank JA; Fisch P; Sondel PM
    Transplantation; 1989 Sep; 48(3):486-95. PubMed ID: 2571206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
    Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
    Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.